ADVERTISEMENT

Conference Report

EASD 2022 — Diabetes drug tirzepatide shows striking results in overweight/obese adults

Shrabasti Bhattacharya   |   26 September 2022

Takeaway

  • A once-weekly dose of tirzepatide 5 mg, 10 mg, or 15 mg demonstrated substantial and sustained body weight reduction in adults who were overweight or obese and did not have diabetes.
  • Tirzepatide also improved several prespecified cardiometabolic risk factors and the quality of life (QoL).
  • Gastrointestinal events of mostly...

          

November Challenge

Ends in 1d 6h
left
right

Topic Challenges

left
right